IRX-2, a novel immunotherapeutic, enhances and protects NK-cell functions in cancer patients

Cancer Immunology, Immunotherapy

Volumn 61, Issue 9, 2012, Pages 1395-1405

  Schilling, B ^a,b   Halstead, E S ^c   Schuler, P ^a,b   Harasymczuk, M ^a,b   Egan, J E ^d   Whiteside, T L ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^c PENN STATE CHILDREN S HOSPITAL   (United States)

^d IRX Therapeutics Inc   (United States)

Author keywords

Head and neck squamous cell cancer (HNSCC); IRX 2; Natural cytotoxicity receptors (NCR); NK cells; Transforming growth factor (TGF )

Indexed keywords

IMMUNOMODULATING AGENT; IRX 2; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 1; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 3; NATURAL KILLER CELL RECEPTOR NKG2D; RECOMBINANT INTERLEUKIN 2; SMAD2 PROTEIN; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CANCER PATIENT; CELL PROTECTION; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG MECHANISM; FLOW CYTOMETRY; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; IN VITRO STUDY; INNATE IMMUNITY; LYMPHOCYTE FUNCTION; NATURAL KILLER CELL; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; UPREGULATION;

CARCINOMA, SQUAMOUS CELL; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; FLOW CYTOMETRY; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-2; K562 CELLS; KILLER CELLS, NATURAL; LEUKOCYTES, MONONUCLEAR; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 1; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 3; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K; PHOSPHORYLATION; SMAD PROTEINS; TRANSFORMING GROWTH FACTOR BETA1; UP-REGULATION;

EID: 84866534385     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-011-1197-x     Document Type: Article

References (40)

1. Wolf GT, Fee WE Jr, Dolan RW, Moyer JS, Kaplan MJ, Spring PM, Suen J, Kenady DE, Newman JG, Carroll WR, Gillespie MB, Freeman SM, Baltzer L, Kirkley TD, Brandwein HJ, Hadden JW (2011) Novel neoadjuvant immunotherapy regimen safety and survival in head and neck squamous cell cancer. Head Neck 33:1666-1674
2. Freeman SM, Franco JL, Kenady DE, Baltzer L, Roth Z, Brandwein HJ, Hadden JW (2011) A phase 1 safety study of an IRX-2 regimen in patients with squamous cell carcinoma of the head and neck. Am J Clin Oncol 34:173-178
3. Berinstein NL, Wolf GT, Naylor PH, Baltzer L, Egan JE, Brandwein HJ, Whiteside TL, Goldstein LC, El-Naggar A, Badoual C, Fridman WH, White JM, Hadden JW (2011) Increased lymphocyte inWltration in patients with head and neck cancer treated with the IRX-2 immunotherapy regimen. Cancer Immunol Immunother. doi:10.1007/s00262-011-1134-z
4. Whiteside TL, ButterWled LH, Naylor PH, Egan JE, Hadden JW, Baltzer L, Wolf GT, Berinstein NL (2011) A short course of neoadjuvant IRX-2 induces changes in peripheral blood lymphocyte subsets of patients with head and neck squamous cell carcinoma. Cancer Immunol Immunother. doi:10.1007/s00262-011-1136- x
5. Hadden J, Verastegui E, Barrera JL, Kurman M, Meneses A, Zinser JW, de la Garza J, Hadden E (2003) A trial of IRX-2 in patients with squamous cell carcinomas of the head and neck. Int Immunopharmacol 3:1073-1081 (Pubitemid 36830852)
6. Czystowska M, Han J, Szczepanski MJ, Szajnik M, Quadrini K, Brandwein H, Hadden JW, Signorelli K, Whiteside TL (2009) IRX-2, a novel immunotherapeutic, protects human T cells from tumor-induced cell death. Cell Death DiVer 16:708-718
7. Egan JE, Quadrini KJ, Santiago-Schwarz F, Hadden JW, Brandwein HJ, Signorelli KL (2007) IRX-2, a novel in vivo immunotherapeutic, induces maturation and activation of human dendritic cells in vitro. J Immunother 30:624-633 (Pubitemid 47229697)
8. Trotta R, Col JD, Yu J, Ciarlariello D, Thomas B, Zhang X, Allard J 2nd, Wei M, Mao H, Byrd JC, Perrotti D, Caligiuri MA (2008) TGF-beta utilizes SMAD3 to inhibit CD16-mediated IFN-gamma production and antibody-dependent cellular cytotoxicity in human NK cells. J Immunol 181:3784-3792
9. Caligiuri MA (2008) Human natural killer cells. Blood 112:461-469
10. Vivier E, Raulet DH, Moretta A, Caligiuri MA, Zitvogel L, Lanier LL, Yokoyama WM, Ugolini S (2011) Innate or adaptive immunity? The example of natural killer cells. Science 331:44-49
11. Gonzalez S, Groh V, Spies T (2006) Immunobiology of human NKG2D and its ligands. Curr Top Microbiol Immunol 298:121-138
12. Brandt CS, Baratin M, Yi EC, Kennedy J, Gao Z, Fox B, Haldeman B, Ostrander CD, Kaifu T, Chabannon C, Moretta A, West R, Xu W, Vivier E, Levin SD (2009) The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans. J Exp Med 206:1495-1503
13. Bryceson YT, March ME, Ljunggren HG, Long EO (2006) Activation, coactivation, and costimulation of resting human natural killer cells. Immunol Rev 214:73-91 (Pubitemid 44707903)
14. Schantz SP, Shillitoe EJ, Brown B, Campbell B (1986) Natural killer cell activity and head and neck cancer: a clinical assessment. J Natl Cancer Inst 77:869-875 (Pubitemid 16031849)
15. Schantz SP, Goepfert H (1987) Multimodality therapy and distant metastases. The impact of natural killer cell activity. Arch Otolaryngol Head Neck Surg 113:1207-1213 (Pubitemid 18035877)
16. Schantz SP, Dimery I, Lippman SM, Clayman GL, Pellegrino C, Morice R (1992) A phase II study of interleukin-2 and interferonalpha in head and neck cancer. Invest New Drugs 10:217-223
17. Szczepanski MJ, Szajnik M, Welsh A, Whiteside TL, Boyiadzis M (2011) Blast-derived microvesicles in sera of acute myeloid leukemia patients suppresses NK cell function via membrane-associated TGF-{beta}1. Haematologica 96:1302-1309
18. Lee JC, Lee KM, Kim DW, Heo DS (2004) Elevated TGF-beta1 secretion and down-modulation of NKG2D underlies impaired NK cytotoxicity in cancer patients. J Immunol 172:7335-7340 (Pubitemid 38747593)
19. Dasgupta S, Bhattacharya-Chatterjee M, O'Malley BW Jr, Chatterjee SK (2005) Inhibition of NK cell activity through TGF-beta 1 by down-regulation of NKG2D in a murine model of head and neck cancer. J Immunol 175:5541-5550 (Pubitemid 41456442)
20. Rabinowich H, Vitolo D, Altarac S, Herberman RB, Whiteside TL (1992) Role of cytokines in the adoptive immunotherapy of an experimental model of human head and neck cancer by human IL-2-activated natural killer cells. J Immunol 149:340-349
21. Heo DS, Snyderman C, Gollin SM, Pan S, Walker E, Deka R, Barnes EL, Johnson JT, Herberman RB, Whiteside TL (1989) Biology, cytogenetics, and sensitivity to immunological eVector cells of new head and neck squamous cell carcinoma lines. Cancer Res 49:5167-5175 (Pubitemid 19239363)
22. Kim GG, Donnenberg VS, Donnenberg AD, Gooding W, Whiteside TL (2007) A novel multiparametric Xow cytometry-based cytotoxicity assay simultaneously immunophenotypes eVector cells: comparisons to a 4 h 51Cr-release assay. J Immunol Meth 325:51-66 (Pubitemid 47238289)
23. Whiteside TL, Bryant J, Day R, Herberman RB (1990) Natural killer cytotoxicity in the diagnosis of immune dysfunction: criteria for a reproducible assay. J Clin Lab Anal 4:102-114
24. Wu JD, Higgins LM, Steinle A, Cosman D, Haugk K, Plymate SR (2004) Prevalent expression of the immunostimulatory MHC class I chain-related molecule is counteracted by shedding in prostate cancer. J Clin Invest 114:560-568 (Pubitemid 39572106)
25. Castriconi R, Cantoni C, Della Chiesa M, Vitale M, Marcenaro E, Conte R, Biassoni R, Bottino C, Moretta L, Moretta A (2003) Transforming growth factor beta 1 inhibits expression of NKp30 and NKG2D receptors: consequences for the NK-mediated killing of dendritic cells. Proc Natl Acad Sci USA 100:4120-4125 (Pubitemid 36418167)
26. WulV S, Pries R, Borngen K, Trenkly T, Wollenberg B (2009) Decreased levels of circulating regulatory NK cells in patients with head and neck cancer throughout all tumor stages. Anticancer Res 29:3053-3057
27. Waldhauer I, Steinle A (2008) NK cells and cancer immunosurveillance. Oncogene 27:5932-5943
28. Sivori S, Vitale M, Morelli L, Sanseverino L, Augugliaro R, Bottino C, Moretta L, Moretta A (1997) p46, a novel natural killer cell-speciWc surface molecule that mediates cell activation. J Exp Med 186:1129-1136 (Pubitemid 27441156)
29. Pende D, Parolini S, Pessino A, Sivori S, Augugliaro R, Morelli L, Marcenaro E, Accame L, Malaspina A, Biassoni R, Bottino C, Moretta L, Moretta A (1999) IdentiWcation and molecular characterization of NKp30, a novel triggering receptor involved in a natural cytotoxicity mediated by human natural killer cells. J Exp Med 190:1505-1516
30. Garcia-Iglesias T, del Toro-Arreola A, Albarran-Somoza B, del Toro-Arreola S, Sanchez-Hernandez PE, Ramirez-Duenas MG, Balderas-Pena LA, Bravo-Cuellar A, Ortiz-Lazareno PC, Daneri-Navarro A (2009) Low NKp30, NKp46 and NKG2D expression and reduced cytotoxic activity on NK cells in cervical cancer and precursor lesions. BMC Cancer 9:186. doi:10.1186/1471-2407-9-186
31. Szczepanski MJ, Szajnik M, Welsh A, Foon KA, Whiteside TL, Boyiadzis M (2010) Interleukin-15 enhances natural killer cell cytotoxicity in patients with acute myeloid leukemia by upregulating the activating NK cell receptors. Cancer Immunol Immunother 59:73-79
32. Chen XM, Xu XQ, Sun K, Hallett WH, Zhao JD, Zhang DL (2008) NKG2D ligands expression and NKG2D-mediated cytotoxicity in human laryngeal squamous carcinoma cells. Scand J Immunol 67:441-447 (Pubitemid 351519387)
33. Clayton A, Mitchell JP, Court J, Linnane S, Mason MD, Tabi Z (2008) Human tumor-derived exosomes down-modulate NKG2D expression. J Immunol 180:7249-7258
34. Martin-Fontecha A, Thomsen LL, Brett S, Gerard C, Lipp M, Lanzavecchia A, Sallusto F (2004) Induced recruitment of NK cells to lymph nodes provides IFN-gamma for T(H)1 priming. Nat Immunol 5:1260-1265 (Pubitemid 41057741)
35. Walzer T, Dalod M, Robbins SH, Zitvogel L, Vivier E (2005) Natural-killer cells and dendritic cells: "l'union fait la force". Blood 106:2252-2258 (Pubitemid 41510793)
36. Cooper MA, Bush JE, Fehniger TA, VanDeusen JB, Waite RE, Liu Y, Aguila HL, Caligiuri MA (2002) In vivo evidence for a dependence on interleukin 15 for survival of natural killer cells. Blood 100:3633-3638 (Pubitemid 35303933)
37. Czystowska M, Szczepanski MJ, Szajnik M, Quadrini K, Brandwein H, Hadden JW, Whiteside TL (2011) Mechanisms of T-cell protection from death by IRX-2: a new immunotherapeutic. Cancer Immunol Immunother 60:495-506
38. Schilling B, Harasymczuk M, Schuler P, Egan JE, Whiteside TL (2011) IRX-2, a novel biologic, favors the expansion of T eVector over T regulatory cells in a human tumor microenvironment model. J Mol Med. doi:10.1007/s00109- 011-0813-8
39. Derynck R, Zhang YE (2003) Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature 425:577-584 (Pubitemid 37280136)
40. Song H, Hur DY, Kim KE, Park H, Kim T, Kim CW, Bang S, Cho DH (2006) IL-2/IL-18 prevent the down-modulation of NKG2D by TGF-beta in NK cells via the c-Jun N-terminal kinase (JNK) pathway. Cell Immunol 242:39-45 (Pubitemid 44894394)